Second quarter 2017, compared to 2016, Group
» Group net sales increased by 33% to SEK 622,897 (469,380)
» Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298)
» Loss before tax amounted to SEK –12,990,707 (–16,473,988)
» Earnings per share (weighted average) amounted to SEK –0.45 (–1.03)
Significant events during the second quarter
» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed
» Episurf Medical obtained further granted patents in Australia, US and Europe
» Episurf Medical strengthened the company’s management group
» Episurf Medical reached milestone of 200 implants
» Episurf Medical continued its communication with the US Food and Drug Administration (FDA)
» Episurf Medical’s Board named Pål Ryfors new CEO and appointed Veronica Wallin as new CFO
» Episurf Medical appointed Dr Michael Manley Special Advisor for the US strategy
Significant events after the second quarter
» Dennis D. Stripe re-assumed the position as non-executive chairman of the board
» Case-report with clinical data of Episealer® patient was published
» Another preclinical paper on the Episealer® Implant published
» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers
» Episurf Medical reported a brief clinical update
» Management group changes in Episurf Medical were announced
» Episurf Medical reached milestone of 250 implants
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 18 August 2017.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlContact:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">INTERIM REPORT 1 APRIL – 30 JUNE, 2017</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Second quarter 2017, compared to 2016, Group
» Group net sales increased by 33% to SEK 622,897 (469,380)
» Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298)
» Loss before tax amounted to SEK –12,990,707 (–16,473,988)
» Earnings per share (weighted average) amounted to SEK –0.45 (–1.03)
Significant events during the second quarter
» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed
» Episurf Medical obtained further granted patents in Australia, US and Europe
» Episurf Medical strengthened the company’s management group
» Episurf Medical reached milestone of 200 implants
» Episurf Medical continued its communication with the US Food and Drug Administration (FDA)
» Episurf Medical’s Board named Pål Ryfors new CEO and appointed Veronica Wallin as new CFO
» Episurf Medical appointed Dr Michael Manley Special Advisor for the US strategy
Significant events after the second quarter
» Dennis D. Stripe re-assumed the position as non-executive chairman of the board
» Case-report with clinical data of Episealer® patient was published
» Another preclinical paper on the Episealer® Implant published
» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independent hospital providers
» Episurf Medical reported a brief clinical update
» Management group changes in Episurf Medical were announced
» Episurf Medical reached milestone of 250 implants
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 18 August 2017.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong><span style="font-size: 10pt;">Second quarter 2017, compared to 2016, Group </span></strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Group net sales increased by 33% to SEK 622,897 (469,380)</p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298)</p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Loss before tax amounted to SEK –12,990,707 (–16,473,988)</p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Earnings per share (weighted average) amounted to SEK –0.45 (–1.03)</p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong><span style="font-size: 10pt;">Significant events during the second quarter </span></strong> </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical obtained further granted patents in Australia, US and Europe</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical strengthened the company’s management group</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical reached milestone of 200 implants</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Episurf Medical continued its communication with the US Food and Drug Administration (FDA)</p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical’s Board named Pål Ryfors new CEO and appointed Veronica Wallin as new CFO</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;">» Episurf Medical appointed Dr Michael Manley Special Advisor for the US strategy<span style="font-size: 10pt;"> </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong><span style="font-size: 10pt;">Significant events after the second quarter </span></strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Dennis D. Stripe re-assumed the position as non-executive chairman of the board</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Case-report with clinical data of Episealer® patient was published</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Another preclinical paper on the Episealer® Implant published</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independ­ent hospital providers</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical reported a brief clinical update</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Management group changes in Episurf Medical were announced</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">» Episurf Medical reached milestone of 250 implants</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical</span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Tel: +46 (0) 709 62 36 69</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Email: <a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 18 August 2017.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => R2
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 153
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2328151/710950.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => INTERIM REPORT 1 APRIL – 30 JUNE, 2017
[Description:protected] => INTERIM REPORT 1 APRIL – 30 JUNE, 2017
[CreateDate:protected] => 2017-08-18T06:30:28Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 2643742
[EncryptedId:protected] => 3B3F4BE6895C271A
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2017-08-18T06:30:00Z
[LastChangeDate:protected] => 2017-08-18T06:30:28Z
[Title:protected] => INTERIM REPORT 1 APRIL – 30 JUNE, 2017
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => RPT
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/interim-report-1-april---30-june--2017,c2328151
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)